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transplantation (HSCT) for children with severe aplastic
anemia (SAA) remains challenges mainly associated with
graft failure and Graft versus Host Disease (GVHD). So it has
been considered in the second choice of treatment status.
But the survival outcomes from AD HSCT in childhood SAA
have improved steadily over the past decade. To answer the
question whether the AD HSCT can be the ﬁrst line therapy
for SAA children we start this single center prospective
upfront AD HSCT study.
Methods: Based on the success of the AD HSCT for children
with SAA previously in our center, the upfront AD HSCT
protocols were approved by the local Ethics Committees. This
trail was registered in ChiCTR (www.chictr.org) in 2010.
Fludarabine (180mg/m2-200mg/m2) +Cyclophosphamide
(120mg/kg) +Anti-thymocyte globulin (ATG, thymoglobulin
10mg/kg) +TBI 3GY were the conditioning regimen and pe-
ripheral blood stem cell was the stem cell source for all the
HSCT children.
Results: 56 children with acquired SAA (include 15VSAA)
were recruited in this upfront AD HSCT study in our center
between Jan 2010 to Jun 2014 with the average age 7.5 (1.8-
17) years old. 21 patients with 10/10 matched unrelated
donor (MUD), 23 patients with 8-9/10mismatched unrelated
donor (MMUD) and 9 patients with 5-8/10 mismatched
related donor (MMRD). All patients did not receive ATG
before HSCT. The average interval from diagnosis to HSCT
was 6.5 (1-102) months. The median nucleated cell doses
were (11.23.4)108/kg and the CD34+ cell doses were
(4.732.37)106/kg. Except 1 graft failure (rescued by sec-
ond HSCT) 55 (98.2%) were engrafted with neutrophil and
platelet recovery occurring at a median of 12 days (range, 9-
18) and 14 (7-68) post-transplant. The cumulative incidence
was 39% and 7% for grade I-II and III-IV acute GVHD, 19% and
2% for mild and moderate chronic GVHD. Compared to our
previous study this intensiﬁed conditioning regimen with
lower graft failure but high post-transplant lymphoprolifer-
ative disease (PTLD). After median follow up 21.75 (2.2-54)
months, 4 of 56 patients died (2 died of PTLD,1 died of severe
aGVHD and another 1 died of CNS infection). 2 patients
suffered poor graft function with long interval from diag-
nosis to HSCT (84 months and 102 months respectively). 5
VSAA patents under uncontrolled infection were rescued by
AD HSCT. The estimated 5-year OS and FFS of the entire
cohort was 92.6% and 88.6%, with no difference between theFigure 1.MUD, MMUD and MMRD cohort (97.7%, 92.3% and 88.9%
respectively).
Conclusions: These excellent outcomes suggest that unma-
nipulated AD PBSC is a good HSCT source for children with
SAA. It’s reasonable to consider AD HSCT as ﬁrst line therapy
for SAA children if suitable donor can be found quickly. HSCT
rescued therapy was important for some under uncontrolled
infection VSAA children. Better strategies are required to
prevent PTLD.285
Hyperthyroidism As a Complication Following
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Thyroid dysfunction is a known complication following he-
matopoietic stem cell transplantation (HSCT) in children.
Most reports in children describe hypothyroidism related to
pre-transplant conditioning regimens, especially total body
irradiation (TBI). We now report the development of post-
transplant thyroid dysfunction on 8 children that developed
hyperthyroidism following HSCT. Three patients were
transplanted for metabolic diseases (two with Sanﬁlippo
Syndrome and one with Adrenal Leukodystrophy, one for
Acute Myelogenous Leukemia, one for Kostman’s Syndrome,
one for Purine Nucleotide Phosphorylase Deﬁciency (PNP),
one for Paroxysmal Nocturnal Hemoglobinuria (PNH) and
one for Chronic Granulomatous Disease (CGD). Five children
were transplanted with Unrelated Umbilical Cord Blood
(URCB), one with matched sibling transplant and two with
adult Matched Unrelated Donor (MUD) transplant. Four of
the ﬁve patients receiving cord blood transplants received
myloablative therapy with Busulfan, Cytoxan and ATG; one
of the URCB patients and one MUD transplant patient
received Fludarabine, Busulfan, Cytoxan and ATG and the
other MUD transplant received Fludarabine, Cytoxan and
two doses of TBI for conditioning. The patient that received
the matched sibling transplant was prepared for transplant
with Busulfan and Melphalan. The onset of hyperthyroidism
ranged between 9 months and 5 years post transplant.
Five patients were off of immunosuppression when
Abstracts / Biol Blood Marrow Transplant 21 (2015) S206eS239 S215hyperthyroidismwas diagnosed and 2 were being treated for
chronic GvHD; one with Etanercept, Cyclosporine and Sol-
umedrol and one with Orapred and Imuran. One patient was
still on prophylactic Tacrolimus when hyperthyroidism was
diagnosed 9 months after transplant. All patients required a
form of ablative therapy. Two received radioactive iodine as
treatment. Three patients received Methimazole alone. One
patient failed Methimazole, received radioactive iodine and
then underwent thyroidectomy revealing follicular carci-
noma. One of the patients did not receive any therapy; he
had Hoshimoto’s thyroidits and went on to develop hypo-
thyroidism. Another patient had a total thyroidectomy that
revealed diffuse hyperplasia. All patients are surviving 1 to 9
years after diagnosis of thyroid disease.Table 1
LV Dysfunction
at day +100
(n[23)
No LV
Dysfunction
at day +100
(n[69)
p
value
Male 14 (61%) 47 (68%) 0.61
Mean Age in Yrs (95% CI) 9.6 (6.3-12.9) 6.9 (5.5-8.2) 0.068
Diagnosis 0.36
Malignancy 12 (51%) 22 (32%)
Immune deﬁciency 5 (21%) 29 (42%)
Bone Marrow Failure 5 (21%) 15 (22%)
Genetic/Metabolic 1 (7%) 2 (3%)
Benign Hematology 0 1 (1%)
Therapy / Conditioning
Previous anthracycline 11 (48%) 18 (26%) 0.070
RIC 12 (52%) 42 (61%) 0.47
Myeloablative 11 (48%) 27 (39%)
Donor 0.11
Autologous 7 (30%) 9 (13%)
Allogeneic 16 (70%) 60 (87%)
Source 0.032
Bone Marrow 11 (48%) 43 (62%)
Cord 0 8 (12%)
PBSC 12 (52%) 18 (26%)
Type 0.14
Auto 7 (30%) 9 (13%)
Related Donor 3 (13%) 8 (12%)
Unrelated Donor 13 (57%) 52 (75%)
Transplant Complications
GVHD 5 (22%) 26 (38%) 0.21
Engraftment Syndrome 1 (4%) 11 (16%) 0.28
Adenovirus 4 (17%) 12 (17%) 1.00
CMV 3 (13%) 19 (28%) 0.26
EBV 7 (30%) 31 (45%) 0.33
Death at 1 year 5 (22%) 14 (20%) 1.00286
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Background: Neuroblastoma (NB) is a pediatric tumor of
neural crest origin. It is one of several small round blue cell
tumors. Patients who have MYC-N ampliﬁed tumors that
respond sub-optimally to initial therapies have poor out-
comes with 30-40% long-term survival. These tumors may
have a higher content of therapy resistant cancer stem cells
that utilize autophagy as an enhanced survival mechanism.
In the following study we identiﬁed a stem cell phenotype in
an MYC-N ampliﬁed neuroblastoma cell line from ATCC (BE-
2) and investigated the activity of two new classes of drugs
(GLUT-1 inhibitors and bisquinolone antimalarials).
Methods: Flow cytometry was utilized to identify stem cell
fractions within an unselected BE-2 population. Brieﬂy, in
side population analysis 1 x 106 cells were incubated with
Hoescht IMDM staining media (1 mcg/ml) and incubated for
30 minutes with Hoechst 33342 dye. Cells were then kept on
ice until ﬂow cytometry analysis. Flow cytometry was per-
formed using a BD FACSAria. Autophagy was measured using
a ﬂow cytometry based assay measuring membrane bound
LC3 (Milipore Inc). Screening assays for drug activity used a
96 well platform with MTT to measure cytotoxicity of bis-
quinolone and GLUT-1 cytotoxicity. Neurospheres were
grown in non-adherent plates to assess activity in this stem
cell enriched screening assay.
Results: Flow cytometry demonstrated a high percent of side
population cells on three separate analyses (11%, 38%, 28% of
live cells). In comparison twomurine breast cancer cells lines
(Clone 66 and 4T1) and human mantle cell line (Granta) side
population fractions were approximately 1% of live cells. A
commercially available bisquinolone, hydroxychloroquine,
demonstrated the ability to inhibit autophagy as measured
by the ﬂow cytometry assay. Using the two in-vitro screening
assays described above, a number of bisquinolone antima-
larials and GLUT-1 inhibitors were assessed for activity and
three compounds were identiﬁed with high activity (Q2-15
antimalarial and STF-04 and STF-05 GLUT-1 inhibitor).
Conclusion: In the following study we describe a large
cancer stem cell population as measured by side population
assay in BE-2 human neuroblastoma cells. Bisquinolone
antimalarial drugs demonstrated the ability to inhibit auto-
phagy. Both bisquinolone antimalarials and GLUT-1inhibitors demonstrated cytotoxic activity in an MTT assay
and activity in a stem cell enriched neurosphere assay. These
two classes of drugs have the potential to improve therapy in
poor prognostic neuroblastoma and studies combining
candidate compounds are ongoing both in cell culture and an
NSG animal model.
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Background: Cardiac evaluation during ﬁrst 100 days after
stem cell transplant (SCT) is usually performed only if clini-
cally indicated, however, patients with mild left ventricular
(LV) dysfunction can be asymptomatic. Scheduled post-SCT
screening at day 100 may identify patients with subacute
cardiac toxicity identiﬁed as LV dysfunction.
Methods:We conducted a single center prospective study to
screen for LV dysfunction after SCT in 100 consecutive pa-
tients. Patients received echocardiography screening prior to
SCT and 100 days post-SCT. Patients were classiﬁed as having
LV dysfunction if echocardiography met at least one of the
